<SEC-DOCUMENT>0001193125-18-107513.txt : 20180404
<SEC-HEADER>0001193125-18-107513.hdr.sgml : 20180404
<ACCEPTANCE-DATETIME>20180404161603
ACCESSION NUMBER:		0001193125-18-107513
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180404
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180404
DATE AS OF CHANGE:		20180404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		18737373

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d564039d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): April&nbsp;4, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-21392</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin
2,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT
STYLE="white-space:nowrap">240.14a-12)</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; <FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; <FONT
STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or
Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744;
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2018, Amarin Corporation plc, or the
Company, issued a press release titled &#147;Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Progress and Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Promotion Initiatives&#148; providing an update on its financial results for the first quarter of 2018. A copy of the Company&#146;s press release is furnished herewith as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information set forth under Item&nbsp;2.02 and in Exhibit 99.1 is intended to be furnished and shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2018, the Company issued a press release titled &#147;Amarin&#146;s <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events.&#148; A copy of the Company&#146;s press release is filed herewith as Exhibit
99.2. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d564039dex991.htm">Press Release, dated April&nbsp;
4, 2018, titled &#147;Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Progress and Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Promotion Initiatives&#148; </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d564039dex992.htm">Press Release, dated April&nbsp;
4, 2018, titled &#147;Amarin&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events&#148;</A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;4, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Thero</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April&nbsp;4, 2018, titled &#147;Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study
Progress and Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Promotion Initiatives&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April&nbsp;4, 2018, titled &#147;Amarin&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular
Events&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d564039dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g564039g81v88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Progress and Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Promotion Initiatives </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Over 97% of Final Patient Visits in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Completed or Scheduled for Near-Term Completion
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, April&nbsp;4, 2018- Amarin Corporation plc&nbsp;(NASDAQ:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular health,&nbsp;today announced an update to its revenue guidance for the first quarter of 2018, reiteration of full year revenue guidance, further progress towards completing
its potential landmark cardiovascular outcomes study, <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> and initiation of previously announced Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> promotion initiatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on lower than expected orders
from Amarin&#146;s wholesaler customers attributed to seasonal factors related primarily to patients&#146; beginning of the new year insurance policy deductible amounts, Amarin estimates that net product revenue for its first fiscal quarter, the
quarter ended March&nbsp;31, 2018, is likely to be approximately $43&nbsp;million, which represents an estimated increase of 25% to 30% over net product revenue in the same period of the prior year. At the beginning of Q1 2018, the company estimated
net product revenue for the quarter would be $45 to $48&nbsp;million. With respect to full year 2018 net product revenue expectations, Amarin continues to believe that it is on track to achieve product revenue of at least $230&nbsp;million, with
such guidance planned to be updated after <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, first quarter net product revenue from
Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sales are negatively impacted by seasonal factors related to patient insurance deductibles. In 2018, Amarin believes that increased beginning of the year insurance policy deductible
amounts at several payor plans made drug coverage more difficult for a significant number of affected patients. The company also believes that wholesaler customers, likely in response to slower than fourth quarter of 2017 Vascepa demand due to these
seasonal effects, decreased their levels of Vascepa inventory. Without such decreases in inventory levels at wholesalers, estimated net product revenue for the quarter ended March&nbsp;31, 2018 would have been approximately $2&nbsp;million higher.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New prescriptions (NRx) of Vascepa reached record levels in March 2018 based on data from Symphony Health and IQVIA. The seasonal factors described above
appear to most impact prescription refills by patients with prior Vascepa prescriptions. Although it appears to be taking longer on average than last year, Amarin anticipates that most patients have largely worked through their beginning of the year
insurance deductibles late in the first quarter and will begin to resume filling prescriptions for Vascepa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medical insurance coverage for Vascepa remains strong for most patients with commercial or Medicare Part D insurance coverage. Beginning of year deductibles under payor plans are not drug
specific. Based on prescription data from third-party sources, Amarin believes that other branded therapies, particularly those for asymptomatic conditions, also experienced prolonged seasonal impact in the first quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to Q1 2018, the company noted that total prescription (TRx) growth reported by third-party sources reflect stronger growth than product shipments
to wholesalers upon which revenues are recognized. Historically prescription growth reported by such third parties has been consistent with growth in product shipments on an annual basis with some quarterly variability observed in these estimates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company intends to provide further updates regarding its operational progress and financial results including in connection with its quarterly report
on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> anticipated in early May. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Final Patient Visits
Progressing as Planned </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin reported that greater than 97% of patients who are alive and active in the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study have either completed their final visit or are scheduled to complete their final visit in the coming weeks with work ongoing to schedule the remaining patients for their final study-related
visits. This progress is consistent with the company&#146;s objective of reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results from this important study before the end of Q3 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As separately reported today, Amarin estimates that the onset of the 1,612<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> primary major adverse
cardiovascular event (MACE) has occurred in the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study and anticipates that MACE from the study will be adjudicated through Q2 2018. This timing is also consistent with reporting <FONT
STYLE="white-space:nowrap">top-line</FONT> results before the end of Q3 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin is intentionally blinded to the results of the study and will remain
blinded to such results until after the study is completed and the database is locked. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expanded
Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Promotion and Disease Awareness Initiatives on Track </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin recently commenced its
previously described pilot awareness initiative including an updated website at www.vascepa.com and limited airings of a television commercial based on the current indication for Vascepa. The company was pleased by the participation of professional
societies and patient advocacy groups for the recent first annual National Triglycerides Day on March 28<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>. Patients are encouraged to learn more about their risks for cardiovascular disease,
including learning more about their triglyceride levels and to consult with their healthcare professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We look forward to continuing to
educate healthcare professionals regarding Vascepa based on its current label and supporting data while advancing <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> to provide broadly sought outcomes </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data,&#148; stated John F. Thero, president and chief executive officer. &#147;Recent studies by other companies highlight that significant cardiovascular risk remains beyond well-controlled
cholesterol management. I have great confidence in the unique clinical attributes of Vascepa to potentially mitigate a substantial portion of this residual cardiovascular risk.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a
biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic
benefits of polyunsaturated fatty acids. Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), Amarin&#146;s first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, is a highly-pure, <FONT
STYLE="white-space:nowrap">omega-3</FONT> fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit <U>www.amarincorp.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules are a single-molecule prescription product consisting of the <FONT
STYLE="white-space:nowrap">omega-3</FONT> acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> manufacturing process
designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple
patents internationally based on the unique clinical profile of Vascepa, including the drug&#146;s ability to lower triglyceride levels in relevant patient populations without raising <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> levels.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">FDA-Approved</FONT> Indication and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt; 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt; 3% and greater than placebo.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult
patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide, cardiovascular
disease (CVD) remains the #1 killer of men and women. In the United States CVD leads to one in every three deaths &#150; one death approximately every 38 seconds &#150; with annual treatment cost in excess of $500&nbsp;billion.<SUP
STYLE="font-size:85%; vertical-align:top">1, 2</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the cardiovascular risk associated with <FONT STYLE="white-space:nowrap">LDL-C,</FONT>
genetic, epidemiologic, clinical and real-world data suggest that patients with elevated triglycerides (TG) (fats in the blood), and <FONT STYLE="white-space:nowrap">TG-rich</FONT> lipoproteins, are at increased risk for cardiovascular disease.<SUP
STYLE="font-size:85%; vertical-align:top"> 3, 4, 5, 6</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leading clinical investigations seeking to address cardiovascular risk reduction beyond
lowering <FONT STYLE="white-space:nowrap">LDL-C</FONT> focus on interrupting the atherosclerotic process (e.g., plaque formation and instability) by beneficially affecting other lipid, lipoprotein and inflammation biomarkers and cellular functions
thought to be related to atherosclerosis and cardiovascular events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including expectations regarding net product revenue from sales of Vascepa for the first quarter of
2018, for the year ended December&nbsp;31, 2018 and inclusive quarterly periods; expectations related to seasonal trends thought to affect sales of Vascepa and their anticipated impact on Vascepa sales in future periods; expectations for continued
final patient visits, estimated event rates, results and related announcement timing associated with Amarin&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study; expectations related to the successful completion of
the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study; and expectations regarding the ability to promote Vascepa and to educate healthcare professionals regarding the efficacy and safety of Vascepa. These forward-looking statements are not
promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission, Amarin&#146;s ability to effectively commercialize Vascepa will depend in
part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve market acceptance of Vascepa, to receive
adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the
factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with the sale of pharmaceutical products, research and development, clinical trials and
related regulatory approvals; the risk that sales may not meet expectations and related cost may increase beyond expectations; the risk that Vascepa may not show clinically meaningful effects in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> or
support regulatory approvals for intended uses; the risk that patents may not be upheld in patent litigation and applications may not result in issued patents sufficient to protect the Vascepa franchise. A further list and description of these
risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or
revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors
and others should note that Amarin communicates with its investors and the public using the company website (<U>http://www.amarincorp.com/</U>), the investor relations website (<U>http://investor.amarincorp.com/</U>), including but not limited to
investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from
time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other website that may be accessed from its website or these channels, shall not be
deemed incorporated by reference in any filing under the Securities Act of 1933. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> American Heart Association. 2018. Disease and Stroke Statistics-2018 Update. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections
through 2035. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP> Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of
cardiovascular disease. <I>Am J Cardiol</I>. 2016;118:138-145. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP> Toth PP, Granowitz C, Hull M, et al.
High triglycerides increase cardiovascular events, medical costs, and resource utilization in a real-world analysis of statin-treated patients with high cardiovascular risk and well-controlled <FONT STYLE="white-space:nowrap">low-density</FONT>
lipoprotein cholesterol [abstract]. <I>Circulation</I>. 2017;136(suppl 1):A15187. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP> Nordestgaard BG.
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease&#151;New insights from epidemiology, genetics, and biology. <I>Circ Res</I>. 2016;118:547-563. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP> Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. <I>Lancet.</I> 2014; 384:
626&#150;635. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646)
<FONT STYLE="white-space:nowrap">378-2992</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com <I> </I></U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries:</I> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristie Kuhl </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finn Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (212) <FONT
STYLE="white-space:nowrap">583-2791</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kristie.kuhl@finnpartners.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d564039dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g564039g81v88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Cardiovascular Outcomes Study Reaches
100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>On Track to Report <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> Results Before the End of Q3 2018 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, April&nbsp;4, 2018- Amarin
Corporation plc&nbsp;(NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health,&nbsp;announced today that its <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
cardiovascular outcomes study of Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) is estimated to have reached the onset of the targeted 1,612 primary major adverse cardiovascular events (MACE) specified in the
study design. The <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study began with patient dosing at the end of 2011. The onset of the targeted number of cardiovascular events in
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is an important milestone toward completion of this potentially landmark study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated onset of
the targeted number of cardiovascular events in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is based on documented events having exceeded 90% of target as reported in January 2018, subsequently reported MACE in the adjudication process, and
projected events based on standard industry methodology. The MACE onset projection was made by independent statisticians and reviewed by Amarin and the independent steering committee for the trial. Each group is blinded to the study results. Amarin
anticipates that MACE from the study will be adjudicated through Q2 2018, consistent with the company&#146;s objective of reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results from this important study before the end of Q3 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously reported, completion of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study does not require reaching exactly 1,612 MACE. The actual
number of events is likely to differ from this study design target. The powering assumptions for the study were based on 1,612 MACE with 90% power to detect a 15% relative risk reduction. A final cumulative MACE tally from inception date of the
study which is slightly above or below 1,612 MACE is not anticipated to have a significant impact on the overall powering of the study results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
maintains its guidance to report <FONT STYLE="white-space:nowrap">top-line</FONT> results from the study before the end of Q3 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited
to be nearing conclusion of this potentially landmark cardiovascular outcomes study,&#148; commented Dr.&nbsp;Steven Ketchum, president of R&amp;D and chief scientific officer of Amarin.&nbsp;&#147;We appreciate the continued dedication of patients
participating in this important study and the continued commitment and hard work at the clinical sites and by the many professionals involved in study conduct and completion. We will work diligently to rapidly
<FONT STYLE="white-space:nowrap">roll-up</FONT> and report the results of the study in the hope that such results can lead to better informed preventative care of patients at high cardiovascular risk.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin is intentionally blinded to the results of the study and will remain blinded to such results until after
the study is completed and the database is locked. Final patient visits will be followed by adjudication of newly reported cardiovascular events in the study, completing data entry for the greater than 33,000 patient years of study in <FONT
STYLE="white-space:nowrap">REDUCE-IT,</FONT> and typical database quality control measures, known as cleaning. This will be followed by the database lock and final efficacy and safety analyses, including analysis of the trial&#146;s primary endpoint
of first MACE events in the study, and the analyses of more than thirty <FONT STYLE="white-space:nowrap">pre-defined</FONT> secondary and tertiary endpoints. Publication of the study design can be found at <U>https://doi.org/10.1002/clc.22692</U>.
The lead author of this paper, published in Clinical Cardiology, is Deepak L. Bhatt, M.D., M.P.H., executive director of the Interventional Cardiovascular Programs at Brigham and Women&#146;s Hospital, professor of medicine, Harvard Medical School
in Boston, Mass. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation
plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential
therapeutic benefits of polyunsaturated fatty acids. Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), Amarin&#146;s first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, is a highly-pure, <FONT
STYLE="white-space:nowrap">omega-3</FONT> fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit <U>www.amarincorp.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules are a single-molecule prescription product consisting of the <FONT
STYLE="white-space:nowrap">omega-3</FONT> acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> manufacturing process
designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple
patents internationally based on the unique clinical profile of Vascepa, including the drug&#146;s ability to lower triglyceride levels in relevant patient populations without raising <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> levels.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">FDA-Approved</FONT> Indication and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt; 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt; 3% and greater than placebo.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN
BE FOUND AT WWW.VASCEPA.COM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce
triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been
approved by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide, cardiovascular disease (CVD) remains the #1 killer of men and women. In the United States CVD leads to one in every three deaths &#150; one death
approximately every 38 seconds &#150; with annual treatment cost in excess of $500&nbsp;billion.<SUP STYLE="font-size:85%; vertical-align:top">1, 2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the cardiovascular risk associated with <FONT STYLE="white-space:nowrap">LDL-C,</FONT> genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood), and <FONT STYLE="white-space:nowrap">TG-rich</FONT> lipoproteins, are at increased risk for cardiovascular disease.<SUP STYLE="font-size:85%; vertical-align:top"> 3, 4, 5, 6</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leading clinical investigations seeking to address cardiovascular risk reduction beyond lowering <FONT STYLE="white-space:nowrap">LDL-C</FONT> focus on
interrupting the atherosclerotic process (e.g., plaque formation and instability) by beneficially affecting other lipid, lipoprotein and inflammation biomarkers and cellular functions thought to be related to atherosclerosis and cardiovascular
events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release contains forward-looking statements, including expectations regarding anticipated MACE onset in the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study, the timing of clinical trial event adjudication, clinical trial results and related
announcement timing associated with Amarin&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study; and expectations related to the successful completion of <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> These
forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission, Amarin&#146;s ability to effectively
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize Vascepa will depend in part on efforts of third parties. Among the factors that could cause actual results to differ materially from those described or projected herein include the
following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that Vascepa may not show clinically meaningful effects in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> or
support regulatory approvals for intended uses; the risk that patents may not be upheld in patent litigation and applications may not result in issued patents sufficient to protect the Vascepa franchise. A further list and description of these
risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or
revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors
and others should note that Amarin communicates with its investors and the public using the company website (<U>http://www.amarincorp.com/</U>), the investor relations website (<U>http://investor.amarincorp.com/</U>), including but not limited to
investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from
time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other website that may be accessed from its website or these channels, shall not be
deemed incorporated by reference in any filing under the Securities Act of 1933. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> American Heart Association. 2018. Disease and Stroke Statistics-2018 Update. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections
through 2035. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP> Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of
cardiovascular disease. <I>Am J Cardiol</I>. 2016;118:138-145. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP> Toth PP, Granowitz C, Hull M, et al.
High triglycerides increase cardiovascular events, medical costs, and resource utilization in a real-world analysis of statin-treated patients with high cardiovascular risk and well-controlled <FONT STYLE="white-space:nowrap">low-density</FONT>
lipoprotein cholesterol [abstract]. <I>Circulation</I>. 2017;136(suppl 1):A15187. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP> Nordestgaard BG.
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease&#151;New insights from epidemiology, genetics, and biology. <I>Circ Res</I>. 2016;118:547-563. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP> Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. <I>Lancet.</I> 2014; 384:
626&#150;635. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646)
<FONT STYLE="white-space:nowrap">378-2992</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com<I> </I></U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries:</I> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristie Kuhl </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finn Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (212) <FONT
STYLE="white-space:nowrap">583-2791</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kristie.kuhl@finnpartners.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g564039g81v88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g564039g81v88.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M! LZ(KY!R"",C'\OJ#7?&2DM#F:L='\+_%'_  C7BR))GVV-_B";/13GY6_
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MJWGCN;>.>%P\4BAT8=&!&017FM6T9UE'Q%_R+.J_]>DO_H!JH?$A2V/D1/\
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MJ:+8^&-5O99(&B6>.',)WKU!')QGT[4X1UO<F3MH>#CP=XF"@?\ "/ZCP/\
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M/+H\[81NIA)_@;V]#_D]E*JG&SW.>4+,^BM.&--M1Z1+_(5R2W9O'8LTAA0
M4 % !0 4 % !0 4""@ H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 A56&" 1Z&@!>G2@ H * "@ H * "@ H * "@04
M#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
-H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
